ACTG175 {speff2trial} | R Documentation |
AIDS Clinical Trials Group Study 175
Description
ACTG 175 was a randomized clinical trial to compare monotherapy with zidovudine or didanosine with
combination therapy with zidovudine and didanosine or zidovudine and zalcitabine in adults infected with the human
immunodeficiency virus type I whose CD4 T cell counts were between 200 and 500 per cubic millimeter.
Usage
data(ACTG175)
Format
A data frame with 2139 observations on the following 27 variables:
pidnum
- patient's ID number
age
- age in years at baseline
wtkg
- weight in kg at baseline
hemo
- hemophilia (0=no, 1=yes)
homo
- homosexual activity (0=no, 1=yes)
drugs
- history of intravenous drug use (0=no, 1=yes)
karnof
- Karnofsky score (on a scale of 0-100)
oprior
- non-zidovudine antiretroviral therapy prior to initiation of study treatment (0=no, 1=yes)
z30
- zidovudine use in the 30 days prior to treatment initiation (0=no, 1=yes)
zprior
- zidovudine use prior to treatment initiation (0=no, 1=yes)
preanti
- number of days of previously received antiretroviral therapy
race
- race (0=white, 1=non-white)
gender
- gender (0=female, 1=male)
str2
- antiretroviral history (0=naive, 1=experienced)
strat
- antiretroviral history stratification (1='antiretroviral naive', 2='> 1 but <=q 52 weeks of prior
antiretroviral therapy', 3='> 52 weeks')
symptom
- symptomatic indicator (0=asymptomatic, 1=symptomatic)
treat
- treatment indicator (0=zidovudine only, 1=other therapies)
offtrt
- indicator of off-treatment before 96pm5 weeks (0=no,1=yes)
cd40
- CD4 T cell count at baseline
cd420
- CD4 T cell count at 20pm5 weeks
cd496
- CD4 T cell count at 96pm5 weeks (=
NA
if missing)
r
- missing CD4 T cell count at 96pm5 weeks (0=missing, 1=observed)
cd80
- CD8 T cell count at baseline
cd820
- CD8 T cell count at 20pm5 weeks
cens
- indicator of observing the event in
days
days
- number of days until the first occurrence of: (i) a decline in CD4 T cell count of at least 50
(ii) an event indicating progression to AIDS, or (iii) death.
arms
- treatment arm (0=zidovudine, 1=zidovudine and didanosine, 2=zidovudine and zalcitabine,
3=didanosine).
Details
The variable days
contains right-censored time-to-event observations. The data set includes
the following post-randomization covariates: CD4 and CD8 T cell count at 20pm5
weeks and the indicator of whether or not the patient was taken off-treatment before 96pm5 weeks.
References
Hammer SM, et al. (1996), "A trial comparing nucleoside monotherapy with combination therapy in
HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter.", New England Journal of Medicine,
335:1081–1090.
[Package
speff2trial version 1.0.2
Index]